Esophageal cancer
Conditions
Interventions
treatment group:apatinib
Sponsors
Shanxi Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged =18 years, male or female; 2. Patients diagnosed with esophageal cancer by histology or cytology; 3. Patients who the researchers believe benefit from treatment; 4. Subjects voluntarily participate in this study and sign the informed consent form (ICF); 5. Patients with compliance are expected to follow up the curative effect and adverse reactions as required by the protocol.
Exclusion criteria
Exclusion criteria: 1. Confirmed allergy to apatinib mesylate tablets and/or its excipients; 2. Pregnant or lactating women; 3. Contraindications of apatinib (patients with active bleeding, ulcer, intestinal perforation, intestinal obstruction, uncontrolled hypertension within 30 days after major operation, grade iii-iv cardiac insufficiency, severe liver and kidney insufficiency should not be allowed); 4. Other conditions considered unsuitable for inclusion by the researcher.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival; | — |
Countries
China
Contacts
Public ContactShiping Guo
Shanxi Cancer Hospital
Outcome results
None listed